Shanghai Haohai Biological Technology Co., Ltd. (HAOHAI BIOTEC) reported to the Hong Kong Stock Exchange that on 10 September 2026 it bought back 48,000 H shares on-market at prices ranging from HKD 16.47 to HKD 16.76, for a total consideration of HKD 0.80 million.

Including this latest transaction, the company has repurchased 807,500 H shares since the current mandate was approved on 29 May 2026. The accumulated buy-backs equal 2.32 % of the 34.78 million H shares outstanding and leave 2.67 million shares available under the 3.48 million-share mandate.

All repurchased shares remain uncancelled; therefore, HAOHAI BIOTEC’s issued share capital stands at 224.98 million ordinary shares, comprising 190.20 million A shares and 34.78 million H shares. The company also holds 3.85 million A shares in treasury. A-share balances were unchanged during the period.

Under Hong Kong Listing Rules, HAOHAI BIOTEC is subject to a moratorium on issuing new shares or disposing of treasury shares until 10 October 2026.